Novo Nordisk (NVO) said Wednesday its US operations will no longer take part in a global initiative on gender representation because of "evolving legal requirements."
The company said that worldwide, it continues to work to achieve representation of at least 45% for each gender by the end of this year.
"We remain committed to non-discrimination and innovation through diverse perspectives, always in compliance with local regulations," the Danish drugmaker said in its Q1 earnings release.
Price: 68.68, Change: +2.39, Percent Change: +3.61
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。